[1]
Gupta, R.C.; Nammi, S.; Bensoussan, A.; Bilinski, K.; Roufogalis, B.D. Interaction between antidiabetic drugs and herbs: an overview of mechanism of action and clinical implication. Diabetol. Metab. Syndr., 2017, 9, 59.
[2]
Rai, A.; Eapen, C.; Prasanth, V.G. Interaction of herbs and glibenclamide: A review. ISRN Pharmacol., 2012, 2012, 1-3.
[3]
Patwardhan, B.; Vaidya, A.D.B.; Chorghade, M. Ayurveda and natural products drug discovery. Curr. Sci., 2004, 86(6), 789-799.
[4]
Said, O.; Fulder, S.; Khalil, K.; Azaizeh, H.; Kassis, E.; Saad, B. Maintaining a physiological blood glucose level with ‘Glucolevel’, a combination of four anti-diabetes plants used in the traditional Arab herbal medicine. Evid. Based Complement. Alternat. Med., 2008, 5(4), 421-428.
[5]
Khanna, N.; Goswami, M.; Sen, P.; Ray, A. Antinociceptive action of Azadirachta indica (neem) in mice: Possible mechanisms involved. Indian J. Exp. Biol., 1995, 33, 848-850.
[6]
Sen, P.; Mediratta, P.K.; Ray, A. Effects of Azadirachta indica A Juss on some biochemical, immunological and visceral parameters in normal and stressed rats. Indian J. Exp. Biol., 1992, 30, 1170-1175.
[7]
Kausik, B.; Chattopadhyay, I.K.; Banerjee, R.K.; Bandyopadhyay, U. Biological activities and medicinal properties of neem (Azadirachta indica). Curr. Sci., 2002, 82(10), 1336-1345.
[8]
Chattopadhyay, R.R.; Chattopadhyay, R.N.; Maitra, S.K. Effect of A. indica on hepatic glycogen in rats. Int. J. Pharmacol., 1993, 25, 174-175.
[9]
Mehrotra, R.; Bajaj, S.; Kumar, D. Use of complementary and alternative medicine by patients with diabetes mellitus. Natl. Med. J. India, 2004, 17(5), 243-245.
[10]
Chacko, E. Culture and therapy: Complementary strategies for the treatment of type-2 diabetes in an urban setting in Kerala, India. Soc. Sci. Med., 2003, 56, 1087-1098.
[11]
Goyal, M. Traditional plants used for the treatment of diabetes mellitus in Sursagar constituency, Jodhpur, Rajasthan-An ethnomedicinal survey. J. Ethnopharmacol., 2015, 174, 364-368.
[12]
Kradjan, W.A.; Takeuchi, K.Y.; Opheim, K.E.; Wood, F.C. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. Pharmacotherapy, 1995, 15(4), 465-471.
[13]
Ravindra, B.P.; Vanishree, S.; Sujatha, S.; Kishore, K.K. Effect of carvedilol on the pharmacokinetics and pharmacodynamics of glipizide. Int. J. Pharm. Pharm. Sci., 2012, 4(3), 133-138.
[14]
Wensing, G. Glipizide: an oral hypoglycemic drug. Am. J. Med. Sci., 1989, 298, 69-71.
[15]
Brian, W.R. Hypoglycemic agents.In: Levy, R.H.; Thummel, K.E.; Tranger, W.F.; Haunsten, P.D.; Eichelbaum, M. Metabolic drug interactions.Philadelphia: , Lippincott Williams & Wilkins;. 2000.
[16]
Yu, C.P.; Wu, P.P.; Hou, Y.C.; Lin, S.P.; Tsai, S.Y.; Chen, C.T.; Chao, P.D. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J. Agric. Food Chem., 2011, 59(9), 4644-4648.
[17]
Trease, G.E.; Evans, W.C. Trease and Evans Pharmacognosy 15thed ; Bailliere Tindall anacox: Landon,. , 2002.
[18]
Wrighton, S.A.; Schuetz, E.G.; Watkins, P.B.; Maurel, P.; Barwick, J.; Bailey, B.S. Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat. Mol. Pharmacol., 1985, 28, 312-321.
[19]
Umathe, S.N.; Dixit, P.V. kumar V.; Bansod K.U.; Wanjari M.M. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition. Biochem. Pharmacol., 2008, 75, 1670-1676.
[20]
Srinivasan, K.; Viswanad, B.; Asrat, L.; Kaul, C.L.; Ramarao, P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res., 2005, 52, 313-320.
[21]
Trinder, P. Modified assay procedure for the estimation of serum glucose using microwell reader. Ann. Clin. Biochem., 1969, 6, 24.
[22]
Astin, J.A. why patients use alternative medicine: Results of a national study. JAMA, 1998, 279(19), 1548-1553.
[23]
Druss, B.G.; Rosenheck, R.A. Association between use of unconventional therapies and conventional medical services. JAMA, 1999, 282(7), 651-656.
[24]
Eisenberg, D.M.; Davis, R.B.; Ettner, S.L. Trends in alternative medicine use in the United States. 1990-1997: results of a follow-up national survey. JAMA, 1998, 280(18), 1569-1575.
[25]
Kuo, G.M.; Hawley, S.T.; Weiss, L.T.; Balkrishnan, R.; Volk, R.J. Factors associated with herbal use among urban multiethnic primary care patients: a cross-sectional survey. BMC Complement. Altern. Med., 2004, 4, 18.
[26]
Rowland, M.; Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications, 3rd ed; Williams & Wilkins: Baltimore, USA, 1995.
[27]
Elliot, M.; Chithan, K.; Theoharis, C.T. The effects of plant flavanoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol. Rev., 2000, 52, 673-751.
[28]
Esmaeili, M.A.; Yazdanparas, R. Hypoglycemic effect of Teucrium polium: studies with rat pancreatic islets. J. Ethnopharmacol., 2004, 99, 27-30.
[29]
Sharma, S.B.; Nassir, A.; Prabhu, K.M.; Murthy, P.S. Antihyperglycemic effect of the fruit-pulp of Eugenia jambolana in experimental diabetes mellitus. J. Ethnopharmacol., 2006, 104, 367-373.
[30]
Yolanda, B.L.; Adriana, G.C. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. J. Nutr. Biochem., 2006, 17, 1-13.
[31]
Ortiz-A, R.R.; Garcia-J, S.; Castillo-E, P.; Ramirez-A, G.; Villalobos, M.R.; Estrada-S, S. α-Glucosidase inhibitory activity of the methanolic extract from Tournefortia hartwegiana: An antihyperglycemic agent. J. Ethnopharmacol., 2007, 109, 48-53.
[32]
Obatomi, D.K.; Bikomo, E.O.; Temple, V.J. Antidiabetic properties of the African mistletoe in streptozotocin-induced diabetic rats. J. Ethnopharmacol., 1994, 43, 13-17.
[33]
Rajeswari, S.; Kumar, A.; Gandhi, M.; Swaminathan, S. Association between lipid profile and liver function tests in diabetic patients. Int. J. Pure App. Biosci., 2014, 2(4), 26-31.
[34]
Philip, R.; Mathias, M.; Suchetha, K.N.; Damodara, G.K.M.; Shetty, K.J. Evaluation of relationship between markers of liver function and the onset of type 2 diabetes. NUJHS, 2014, 4(2), 90-93.
[35]
Agarawa, J. Prevalence of elevated hepatic enzymes among north Indian patients with type 2 diabetes mellitus. SUJHS, 2015, 1(1), 3-6. (b) Maxwell, D.B.; Fisher, E.A.; Ross-Clunis, H.A.; Estep, H.L. Serum alkaline phosphatase in diabetes mellitus. J. Am. Coll. Nutr., 1986, 5(1), 55-59.
[36]
Robert, J.K.; Barbara, B. Hodgson Saunders Nursing Drug Handbook 2017 - E-Book; Elsevier: United states of America, 2017.
[37]
Kale, B.P.; Kothekar, B.P.; Tayade, H.P.; Jaju, J.B.; Mateenuddin, M. Effect of aqueous extract of Azardirachta indica leaves on hepatotoxicity induced by antitubercular drugs in rats. Int. J. Pharmacol., 2003, 35, 177-180.
[38]
Chattopadhyay, R.R.; Sarkar, S.K.; Ganguly, S.; Banerjee, R.N.; Basu, T.K.; Mukherjee, A. Hepatoprotective activity of Azadirachta indica leaves on paracetamol induced hepatic damage in rats. Indian J. Exp. Biol., 1992, 30, 738-740.
57
6
1
1